We are live on ! Find out more
SLN

Silence Therapeutics
SLN

64 hedge funds and large institutions have $588M invested in Silence Therapeutics in 2024 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,500% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 2

88% more funds holding

Funds holding: 34 → 64 (+30)

70% more capital invested

Capital invested by funds: $345M → $588M (+$243M)

55% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 11

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

0.76% more ownership

Funds ownership: 19.11% → 19.87% (+0.76%)

Holders
64
Holders Change
+30
Holders Change %
+88.24%
% of All Funds
0.92%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.12%
New
32
Increased
17
Reduced
11
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$44.1M
2
TCM
TCG Crossover Management
California
+$25.9M
3
LGM
Logos Global Management
California
+$23.4M
4
NI
Nextech Invest
Switzerland
+$20.7M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$13.6M

Top Sellers

Rank Fund Capital Flow
1
LOAMU
Lombard Odier Asset Management (USA)
New York
-$32.4M
2
LOAME
Lombard Odier Asset Management (Europe)
United Kingdom
-$29.9M
3
BI
BVF Inc
California
-$26.2M
4
ACM
Aquilo Capital Management
California
-$10.2M
5
DTC
Deep Track Capital
Connecticut
-$6.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
Woodline Partners
California
$5.15M +$4.11M +189,108 +384%
NCM
27
Nantahala Capital Management
Connecticut
$4.32M +$4.35M +200,000 New
HSBC Holdings
28
HSBC Holdings
United Kingdom
$3.84M – – –
Marshall Wace
29
Marshall Wace
United Kingdom
$3.01M +$3.03M +139,191 New
SSA
30
Schonfeld Strategic Advisors
New York
$2.87M +$1.82M +83,800 +170%
BFM
31
Boothbay Fund Management
New York
$2.75M +$2.77M +127,224 New
Two Sigma Investments
32
Two Sigma Investments
New York
$2.32M +$2.33M +107,212 New
Renaissance Technologies
33
Renaissance Technologies
New York
$2.24M +$1.67M +76,798 +283%
CF
34
Cantor Fitzgerald
New York
$2.24M -$941K -43,294 -29%
Walleye Capital
35
Walleye Capital
New York
$1.98M +$2M +91,819 New
BC
36
BIT Capital
Germany
$1.92M +$1.93M +89,000 New
Two Sigma Advisers
37
Two Sigma Advisers
New York
$1.67M +$1.68M +77,400 New
UOC
38
UBS O'Connor
Illinois
$1.56M -$456K -20,975 -23%
UBS Group
39
UBS Group
Switzerland
$1.55M +$42.9K +1,972 +3%
Citigroup
40
Citigroup
New York
$1.26M – – –
AGP
41
Artia Global Partners
Florida
$1.13M +$1.14M +52,476 New
Citadel Advisors
42
Citadel Advisors
Florida
$922K +$455K +20,945 +96%
ACM
43
ADAR1 Capital Management
Texas
$866K +$867K +39,900 +21,000%
CSS
44
Cubist Systematic Strategies
Connecticut
$784K +$789K +36,281 New
William Blair & Company
45
William Blair & Company
Illinois
$549K -$2.52K -116 -0.5%
Geode Capital Management
46
Geode Capital Management
Massachusetts
$484K – – –
Goldman Sachs
47
Goldman Sachs
New York
$470K +$473K +21,739 New
TI
48
Trexquant Investment
Connecticut
$455K +$457K +21,047 New
RG
49
Rathbones Group
United Kingdom
$430K +$433K +19,906 New
JF
50
Jump Financial
Illinois
$406K +$409K +18,800 New
1
2
3

SLN Hedge Fund Activity: Q1 2024 in Review

64 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2024, worth a combined $588M — up 70% from $345M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SLN positions and 2 closed out — a net gain of 30 holders — while 17 added to existing stakes and 11 trimmed.

The largest buyer was Redmile Group, opening a new position worth an estimated $44.1M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $32.4M.

  • 64 institutional investors held Silence Therapeutics (SLN) as of Q1 2024, up from 34 in Q4 2023.
  • Funds reported $588M of Silence Therapeutics stock for Q1 2024, up 70% quarter-over-quarter.
  • 32 funds opened new Silence Therapeutics positions in Q1 2024 and 2 closed out, a net change of +30 holders.
  • The largest Silence Therapeutics buyer in Q1 2024 was Redmile Group, an estimated $44.1M added.
  • The largest Silence Therapeutics seller in Q1 2024 was Lombard Odier Asset Management (USA), an estimated $32.4M sold.

Based on aggregated 13F filings for Q1 2024.